Theralase(R) Closes $1.3 M Non-Brokered Private Placement

Core Viewpoint - Theralase Technologies Inc. has successfully closed a non-brokered private placement offering, raising approximately $CAN 1,334,650 to support its clinical study and general corporate purposes [1][2][3]. Group 1: Offering Details - The company issued a total of 7,850,882 Units at a price of $CAN 0.17 per Unit, resulting in gross proceeds of about $CAN 1,334,650 [2]. - Each Unit consists of one common share and one common share purchase warrant, with the warrant allowing the holder to acquire an additional common share at an exercise price of $CAN 0.21 for five years [2]. - A finder's fee of $31,658 was paid, which included $15,470 in cash and $16,188 in common shares, along with the issuance of 186,221 non-transferable finder warrants [4]. Group 2: Use of Proceeds - The proceeds from the financing will be utilized to advance the Phase II Non-Muscle Invasive Bladder Cancer clinical study, as well as for working capital and general corporate purposes [3]. Group 3: Regulatory and Compliance Information - All securities issued under the Offering will be subject to a four-month and one-day hold period, expiring on April 24, 2026, and the Offering is pending final acceptance from the TSX Venture Exchange [6].